Tagged with Valeant

Pharma The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is conducted and, as such, we have seen the rise (and sometimes fall) of a new breed of companies that some…

Valeant Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson. Following the loss of nearly 93 percent of its value, the much maligned firm has announced that it will adopt…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…

pharma Egypt is back in business, with economic growth and investor confidence in Egypt nearly back to levels seen in 2010, GDP growth up to four percent, and several high profile deals with multinationals. PharmaBoardroom spoke to Hisham A Fahmy, the CEO of the American Chamber of Commerce, about keeping Egypt…

generics At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses the company’s objectives for Spanish speaking Latin America and how it plans to leverage the recently acquired Bausch+Lomb business to…

government relations With a Master’s Degree in Marketing Science from the University of Leicester and a Degree in Management Information Systems from Université du Québec à Montréal Jacques Dessurealt has had a fruitful career in the pharmaceutical industry with some of the biggest names like Bristol Myer-Squibb and Novartis. He talks with…